Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio

Sergio Serrano-Villar1*, María Jesús Pérez-Elias1, Fernando Dronda1, José Luis Casado1, Ana Moreno1, Ana Royuela2, José Antonio Pérez-Molina1, Talía Sainz3, Enrique Navas1, José Manuel Hermida1, Carmen Quereda1, Santiago Moreno1

1 Department of Infectious Diseases, Institute for Health Research (IRICYS), University Hospital Ramón y Cajal, Madrid, Spain, 2 CIBER, Epidemiología y Salud Pública, Clinical Biostatistics Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain, 3 Laboratory of Molecular Immune Biology, University Hospital Gregorio Marañón, Madrid, Spain

Abstract

Background: A low CD4/CD8 ratio has been identified in the general population as a hallmark of immunosenescence and a surrogate of all-cause mortality. We aimed to investigate in treated HIV-infected individuals the relationship between the CD4/CD8 ratio and serious non-AIDS events.

Methods: Case-control study within a prospective hospital-based cohort of HIV-infected subjects during at least one year of ART-mediated viral suppression. Cases were patients with serious non-AIDS events (non-AIDS malignancies, cardiovascular disease, and end-stage kidney disease), and controls individuals who did not developed non-AIDS events during follow-up. Data were analyzed using ROC analysis and multivariate logistic regression. Conditional logistic regression was performed in 200 cases/controls matched by age, sex, nadir CD4 and proximal CD4 counts.

Results: We analyzed 407 subjects (109 cases, 298 controls). The CD4/CD8 ratio was lower in cases (0.44 vs. 0.70, P<0.0001), with higher discriminatory ability for the detection of non-AIDS events than the CD4 count, CD8 count and nadir CD4. Multivariate analyses (adjusted for age, sex, nadir CD4, proximal CD4 count, year of ART initiation and ART duration) confirmed the independent association of a low CD4/CD8 ratio with the risk of non-AIDS morbidity (per CD4/CD8 ratio quartile decrease, OR, 2.9; 95% CI, 1.3–6.2) and non-AIDS mortality (OR, 2.8; 95% CI, 1.5–5.3).

Conclusions: The CD4/CD8 ratio provides additional information to the CD4 counts and nadir CD4 in treated HIV-infected individuals, since it is independently associated with the risk of non-AIDS-related morbidity and mortality. This association is robust and maintained within different subgroups of patients.

Introduction

Modern antiretroviral therapy (ART) regimens are among the greatest successes of modern medicine and have shifted the prognosis of HIV-infected patients from years to decades. This remarkable improvement in long-term life expectancy has brought to the scenario a raising concern about the so-called non-AIDS defining illnesses, a group of conditions generally associated with aging, including cardiovascular disease, renal disease, liver disease, neurocognitive disorders, and non-AIDS malignancies [1–6]. Overall, these conditions increase morbidity and mortality despite effective ART [7,8]. The changing clinical picture of HIV infection has led to a shift in management of HIV infection, to the extent that the usefulness of CD4+ T-cell counts in patients who have reached full HIV RNA suppression has come to debate [9].

Persistent immune activation during treated HIV infection is widely accepted as a driver of non-AIDS-associated diseases [10,11]. Different conditions are thought to fuel immune activation during treated HIV-infection, including increased bacterial translocation due to a chronically injured mucosa-associated lymphoid tissue (MALT), asymptomatic replication of coinfecting pathogens, especially cytomegalovirus (CMV) and residual viral replication in HIV reservoirs [12–16]. Remarkably, HIV-infected subjects display different changes in the adaptive immune system that are shared by the elderly, namely “immunosenescence”, a global term used to describe the observed age-associated decline in immune competence [6], and immune activation is widely accepted as the major driving factor of...
immunosenescence that ultimately yield to disease progression and adverse outcomes [13], including age-associated disease.

Outside HIV infection, a low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of all-cause mortality [17–20]. Interestingly, a low CD4/CD8 ratio is practically a universal finding in ART-naïve patients and remains low in a substantial proportion of patients who present adequate CD4+ T-cell count recovery. Nevertheless, the clinical significance of a failure to normalize the CD4/CD8 ratio under suppressive ART remains obscure. We have previously described in long-term virally suppressed HIV-infected subjects a negative correlation between the CD4/CD8 ratio and immune activation and immunosenescence [21,22], and we also observed that is independently associated with surrogate markers of age-associated disease [23]. Hence, we hypothesized that the CD4/CD8 ratio in ART treated patients can provide additional information to the CD4+ T-cell counts and nadir CD4 and be independently associated to non-AIDS associated morbidity and mortality.

Methods

Study Design, Participants, Setting and Eligibility

We conducted a case-control study within a clinic-based cohort formed in 1999 of over 2,600 HIV-infected patients receiving care in University Hospital Ramón y Cajal, Madrid. We included HIV-infected adults in this cohort during at least one year of ART-mediated viral suppression. Cases were subjects who developed non-AIDS malignancies, cardiovascular disease, and end-stage chronic kidney disease with available CD4+ and CD8+ T-cell counts measured during routine care and no more than 6 months before the event. For each case, we aimed to identify two ART-suppressed unmatched controls at least one year under viral suppression, in whom the absence of serious non-AIDS events could be ascertained. For the analysis, we used for the last available CD4/CD8 ratio at censoring, which occurred at the time of the event in cases and at the last clinic visit in controls until September 2012. The overall selection of study participants in our study population is described in Figure 1. Since 2004, patients who were naïve and started ART at our clinics are enrolled in a nationwide, ongoing prospective multi-center cohort (CoRIS) of HIV-positive subjects. CoRIS is a joint activity of the Research Network of Excellence (AIDS research network, RIS), which incorporates basic scientists, virologists, immunologists, clinicians, epidemiologists and statisticians. Internal quality controls are performed annually and 10% of data are externally audited every year. This database collects demographic and clinical data, risk behaviors, ART history, prior opportunistic diseases, comorbidities, serologic and immunovirological data and specific data on non-AIDS diseases. All subjects from our center in CoRIS database with available CD4/CD8 ratio were included in the study, identifying 348 subjects fulfilling the inclusion criteria. Since we aimed to analyze at least 100 cases, we also searched cases in our general prospective database, in which patients are incorporated since 1999 and therefore, many of them are not enrolled in CoRIS. We carefully reviewed the medical records to ascertain the presence or absence of non-AIDS events. The final study sample included 407 subjects (109 cases and 298 controls).

Ethics Statement

This study was conformed to the principles or the Declaration of Helsinki and the Good Clinical Practice Guidelines and was approved by our Independent Ethics Committee (Hospital Ramón y Cajal, 28034 Madrid, Spain). All study subjects gave their written informed consent to be included in the database and to analyze the data for investigational purposes.

Definition on non-AIDS Events

Non-AIDS events involve a broad spectrum of disease, and several definitions to approach the problem in the setting of HIV infection have been used, from subclinical disease such as increased carotid intima-media thickness or osteoporosis to end-stage organ diseases. Since two previous studies in HIV-infected patients specifically described that the CD4/CD8 ratio was associated to cardiovascular disease [24] and Hodgkin lymphoma [25], we used as outcome variable cardiovascular events and non-AIDS defining neoplasias. Data on Hodgkin’s lymphoma were analyzed separately as Hodgkin’s lymphoma is not generally considered an age-associated disease [26]. Since chronic kidney disease is usually considered a chronic heart disease risk equivalent [27], we also included subjects with end-stage kidney disease in the definition, according to the stages defined by the Kidney Disease Quality Outcome Initiative [28]. To avoid the potential confounding effect of alcohol abuse and hepatitis C virus (HCV), we excluded patients with end-stage liver disease and hepatocarcinoma. Hence, cases were HIV-infected ART-suppressed patients who developed non-AIDS defining malignancies, excluding hepatocarcinoma and non-melanomatous skin cancers, ischemic heart disease (myocardial infarction, percutaneous coronary angioplasty, coronary artery bypass surgery), stroke (ischemic or hemorrhagic), or end-stage kidney disease or. We defined non-AIDS related mortality when the death was caused by any of these conditions.

Statistical Analysis

Means for variables with a normal distribution were compared using the $t$ test and with the Mann-Whitney’s $U$ test when distribution of data departed from normality. We compared the CD4/CD8 ratio in cases and controls, and the Spearman correlation coefficient was used to analyse the correlation between the CD4/CD8 ratio and continuous variables. The performance of the CD4/CD8 ratio to discriminate cases and controls was analyzed using the Receiver Operating Characteristic (ROC) curve and calculating the area under curve (AUC). The optimal cutoff was determined by maximizing the sum of sensitivity and specificity. We compared the AUC of the CD4/CD8 ratio with that of the CD4+ T-cell count, CD8+ T-cell count and nadir CD4 using the equality test of ROC areas.

Given that cases and controls showed significant differences in nadir CD4, proximal CD4+ T-cell count and cumulative ART exposure, we attempted to address the potential problem of confounding on the association between non-AIDS events, as dependent variable, and the CD4/CD8 ratio by multivariate logistic regression analysis. Nadir CD4 and cumulative ART exposure were incorporated in the models since they have been previously associated with non-AIDS events [29,30] as well as with surrogate markers of age-associated disease [31,32]. Given that the span of entrance in the cohort included a long period, and that individuals starting ART more recently might have received more effective ART, the year of entrance in the cohort was also considered. CD4+ T-cell counts could not be introduced in the models because of collinearity with the CD4/CD8 ratio. Therefore, the model included age, sex, cumulative ART exposure, nadir CD4, year of entrance in the cohort, CD4/CD8 ratio (categorized per quartiles and by the cutoff of 0.4 identified in the ROC analysis) and a potential interaction between the CD4/CD8 ratio and cumulative ART exposure, that was not significant, and was removed from the final model. We specifically analyzed...
the association between the CD4/CD8 ratio and non-AIDS-associated mortality following the same strategy. To evaluate whether the CD4/CD8 ratio may maintain the association with non-AIDS events in subjects with low nadir CD4, we re-applied the same logistic regression model in the subgroup of patients with low CD4 nadir (<200 cells/μL). Similarly, we explored whether the CD4/CD8 ratio may remain associated with non-AIDS events in subjects with CD4 recovery by reapplying the model to the subgroup of individuals with CD4 count >350 cells/μL.

In order to evaluate whether the CD4/CD8 ratio might provide additional information to the CD4+ T-cell count and the nadir CD4 as a predictor of non-AIDS events, and since these two variables were imbalanced between cases and controls, we performed a nested case-control analysis. We used the Mahapick procedure, a multivariate matching procedure based on a Mahalanobis scoring algorithm, to match cases and controls simultaneously based on age, sex, nadir CD4, and proximal CD4+ T-cell counts, allowing the matching if only one control had complete data. We obtained 200 matched cases and controls in whom we assessed the CD4/CD8 ratio as a predictor of non-AIDS events using conditional logistic regression and adjusting by date of ART initiation and cumulative ART exposure. The null hypothesis was rejected by a type I error, \( P<0.05 \). Statistical analyses were performed using Stata v. 12.0 (StataCorp LP College Station, Texas, USA).

**Results**

**General Characteristics of the Study Population and between-groups Comparisons**

We analyzed 407 subjects (109 cases and 298 controls), 74% of Caucasian ethnicity and 37% reporting previous injection drug use. Mean age was 43 years [IQR 37–48], median CD4 nadir 194 cells/μL [IQR 74–293], median CD4+ T-cell count 504 cells/μL [IQR 341–661], median CD4/CD8 ratio 0.62 [IQR 0.42–0.88] and mean cumulative ART exposure 4 years [IQR 2–7].

The general characteristics of the study population are summarized in **Table 1**. In the univariate comparisons between cases and controls, no statistically significant differences in sex distribution, geographic origin or risk factors for HIV acquisition were observed. However, patients who developed non-AIDS events were significantly older compared to controls (46 years vs. 41, \( P<0.0001 \)) and showed significantly longer cumulative ART exposure (9.7 years vs. 3.9, \( P<0.0001 \)), lower CD4 nadir (124 cells/μL vs. 219, \( P<0.0001 \)) and lower CD4+ T-cell count (371 cells/μL vs. 536, \( P=0.005 \)). These differences disappeared in the subgroup matched by age, gender, nadir CD4 and CD4+ T-cell count, with the exception of cumulative ART exposure, being still longer among cases.

**Figure 2** illustrates the CD4/CD8 Ratio in controls and in cases across the different types of events (for a description of the events, see **Table 2**). The CD4/CD8 in controls [0.70 [IQR 0.46–0.94]] was significantly higher compared to the ratio in subjects who developed non-AIDS events [0.46 [IQR 0.31–0.68], \( P<0.0001 \)].
including non-AIDS defining malignancies (N = 35) [0.44 (IQR 0.25–0.71), P = 0.0001], Hodgkin lymphoma (N = 10) [0.41 (IQR 0.33–0.57), P = 0.0039], ischemic heart disease (N = 38) [0.47 (IQR 0.32–0.63), P = 0.0001], stroke (N = 15) [0.46 (IQR 0.28–0.83), P = 0.013], and end-stage kidney disease (N = 9) [0.33 (IQR 0.32–0.53), P = 0.028]. The CD4/CD8 ratio was also significantly lower in subjects with non-AIDS associated mortality (N = 29) [0.33 (IQR 0.22–0.46), P < 0.0001].

Relations with the CD4/CD8 Ratio
We analyzed the associations between the study variables and the CD4/CD8 ratio. The CD4/CD8 ratio showed weak albeit statistically significant correlations with age (Rho = 0.152, P = 0.0001), nadir CD4 (Rho = −0.20, P < 0.001) and cumulative ART exposure (Rho = 0.14, P = 0.042) and was significantly lower in men compared to women (0.71 Vs. 0.61, P = 0.032).

Discriminatory Ability of the CD4/CD8 Ratio for the Prediction of non-AIDS Events
The discriminatory ability of the CD4/CD8 ratio was explored by obtaining the AUC. The CD4/CD8 ratio showed the best AUC (0.720, 95% CI 0.662–0.777), significantly higher than that for CD4+ T-cell count (0.671), CD8+ T-cell count (0.435) or nadir CD4 (0.662). The most accurate cutoff of the CD4/CD8 ratio for the detection of non-AIDS events in a sensitivity/specifity plot was 0.4, with a sensitivity of 0.83 and a specificity of 0.45.

Associations between the CD4/CD8 Ratio and non-AIDS Related Morbidity and Mortality
Univariate and multivariate analyses are summarized in Table 3. In the univariate analysis, a lower CD4/CD8 ratio was associated with increased risk of non-AIDS events (per quartile decrease; OR, 2.0; 95% CI, 1.6–2.5). In the multivariate analysis, after adjusting by gender, age, nadir CD4, date of ART initiation and cumulative ART exposure, subjects with lower CD4/CD8 ratio displayed greater risk of non-AIDS events (per quartile decrease; OR 2.6; 95% CI, 1.7–4.0; for CD4/CD8 ratio <0.4; OR 5.1; 95% CI, 2.3–12.4). Following the same strategy, a low CD4/CD8 ratio was a predictor of non-AIDS mortality (per quartile decrease; OR, 2.8; 95% CI, 1.5–5.3; for CD4/CD8 ratio <0.4; OR, 4.5; 95% CI, 1.7–11.8).

Table 1. General characteristics of the study population and in the nested case/control study.

| Study sample | Matched Study |
|--------------|---------------|
| N = 407 | N = 200 |
| Cases | Controls | P value | Cases | Controls | P value |
| N = 109 | N = 298 | | N = 100 | N = 100 | |
| Sex, % | | 0.468 | 1.0 |
| Male | 77.9 | 81.1 | 81.0 | 81.0 |
| Female | 22.1 | 18.8 | 19.0 | 19.0 |
| Age* | 46 [43–49] | 41 [34–47] | < 0.0001 | 46 [42–50] | 46 [42–50] | 1.0 |
| Geographic Origin, % | | 0.301 | 0.154 |
| Western Europe | 70.9 | 90.5 | 80.0 | 93.0 |
| South America | 20.3 | – | 15.0 | – |
| Africa | 5.8 | 9.5 | 3.0 | 7.0 |
| Other | 3.1 | – | 2.0 | – |
| Risk category, % | | 0.098 | 0.104 |
| Previous IDU | 48.4 | 32.9 | 47.6 | 29.2 |
| Heterosexual | 23.8 | 19.9 | 28.6 | 19.8 |
| Homosexual | 21.3 | 40.8 | 14.3 | 42.7 |
| Other/Unknown | 6.5 | 6.6 | 9.5 | 8.3 |
| CDC HIV Classification, % | | 0.008 | 0.242 |
| A | 27.5 | 61.2 | 33.6 | 42.3 |
| B | 37.2 | 18.8 | 31.1 | 27.4 |
| C | 33.3 | 19.9 | 36.3 | 30.3 |
| Cumulative ART exposure (years)* | 9.7 [5.5–13.6] | 3.9 [2.3–5.4] | < 0.0001 | 9.8 [5.4–13.5] | 4.3 [2.4–6.2] | < 0.0001 |
| CD4 nadir (cell/L)* | 124 [33–221] | 219 [107–303] | < 0.0001 | 121 [40–231] | 120 [46–233] | 0.9105 |
| CD4+ count (cell/L)* | 371 [225–586] | 536 [407–678] | < 0.0001 | 404 [260–588] | 415 [173–589] | 0.689 |
| CD8+ count (cell/L)* | 880 [582–1185] | 791 [588–1053] | 0.007 | 925 [636–1245] | 715 [501–978] | 0.002 |
| CD4/CD8 ratio* | 0.44 [0.30–0.68] | 0.70 [0.48–0.94] | < 0.0001 | 0.46 [0.29–0.66] | 0.62 [0.40–0.90] | 0.001 |

*Expressed as median (P25–P75).

doi:10.1371/journal.pone.0085798.t001
To assess whether the CD4/CD8 ratio might maintain the independent association with non-AIDS events among subjects with low nadir CD4, we re-applied the model in the subgroup of patients with nadir CD4 below 200 cells/µL (N = 212) and the CD4/CD8 ratio remained independently associated to non-AIDS events (per quartile decrease; OR 2.8; 95% CI 1.2–2.2). Also, we analyzed whether the CD4/CD8 ratio might remain independently associated to non-AIDS events in subjects with successful immunological response to ART by re-applying the model in those with higher CD4+ T-cell counts, as it was even stronger in the subgroup of patients with low nadir CD4, as well as in those with higher CD4+ T-cell counts, or in a subpopulation of 200 cases and controls matched by age, gender, nadir CD4 and CD4+ T-cell count.

In our view, the importance of the HIV viral load and CD4+ T-cell count in the clinical management of HIV-infected subjects and as predictors of clinical outcomes left little room in past years for any other clinically useful marker. The CD4/CD8 ratio has proved to be useful in a number of areas. In the setting of HIV infection, this ratio was identified before the introduction of the highly active ART in 1996 as a predictor of development of AIDS [33]. More recently, in a study in the Swiss cohort a low CD4/CD8 ratio before initiation of ART was a predictor of Hodgkin lymphoma [25], and in a case-control study the CD4/CD8 ratio was independently associated with subclinical atherosclerosis [24], which in turn has been associated with immune activation and immunosenescence [34], as most of non-AIDS-associated conditions [10]. These observations provided support to speculate that the CD4/CD8 ratio might be a marker of non-AIDS-related diseases in treated HIV-infected patients. Outside HIV infection, a low CD4/CD8 ratio, namely the immune risk profile, has been proposed as a surrogate marker of the collection of immune-related defects that defines “immunosenescence”–a phenomenon characterized by the T-cell proliferation and differentiation resulting in the generation of antigen experienced, highly differentiated and dysfunctional T-cells [13]– and correlated with all-cause mortality in the elderly [18–20,35]. Given these studies, we recently evaluated the biological and clinical significance of the CD4/CD8 ratio in treated HIV infection. First, in an exploratory study in long-term virally suppressed adults we found that the CD4/CD8 ratio inversely correlated with activated CD4+ T-cell count or nadir CD4 to proximal CD4+ T-cell count, and senescence (CD57+). In this study in long-term virally suppressed adults we found that the CD4/CD8 ratio was strongly associated with the risk of non-AIDS morbidity and mortality. Remarkably, the CD4/CD8 ratio was consistently lower across all types of non-AIDS events included in the definition (ischemic heart disease, stroke, end-stage kidney disease, and non-AIDS malignancies) and performed better than the CD4+ T-cell count, CD8+ T-cell count or nadir CD4 to discriminate subjects at risk of serious non-AIDS events. Noteworthy, this association hold robustly and was independent of nadir CD4 and proximal CD4+ T-cell counts, as it was even stronger in the subgroup of patients with low nadir CD4, as well as in those with higher CD4+ T-cell counts, or in a subpopulation of 200 cases and controls matched by age, gender, nadir CD4 and CD4+ T-cell count.

Discussion

In this study in ART-treated HIV-infected patients, a low CD4/CD8 ratio was strongly associated with the risk of non-AIDS morbidity and mortality. Remarkably, the CD4/CD8 ratio was consistently lower across all types of non-AIDS events included in the definition (ischemic heart disease, stroke, end-stage kidney disease, and non-AIDS malignancies) and performed better than the CD4+ T-cell count, CD8+ T-cell count or nadir CD4 to discriminate subjects at risk of serious non-AIDS events. Note-
| Explanatory logistic regression (All sample) | 4<sup>th</sup> Qrt. | 3<sup>rd</sup> Qrt. | 2<sup>nd</sup> Qrt. | 1<sup>st</sup> Qrt. | OR per Qrt. Decrease | CD4/CD8 ratio <0.4 |
|-------------------------------------------|------------------|------------------|------------------|------------------|---------------------|-----------------------|
|                                          | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| # Cases/Controls                          | 11/91 | 19/83 | 31/71 | 48/53 | 109/298 | 109/298 |
| Unadjusted                                | 1.0   | 1.89 (0.85, 4.21) | 0.118 | 3.61 (1.69, 7.68) | 0.001 | 7.49 (3.58, 15.66) | <0.0001 | 1.96 (1.57, 2.45) | <0.0001 | 4.79 (2.91, 7.90) | <0.0001 |
| Adjusted<sup>a</sup>                      | 1.0   | 2.57 (0.63, 10.54) | 0.188 | 10.61 (2.78, 40.50) | 0.001 | 15.77 (3.65, 68.18) | <0.0001 | 2.56 (1.66, 3.94) | <0.0001 | 5.11 (2.31, 12.42) | <0.0001 |
| # Cases/Controls in subjects with nadir <200 | 4/24 | 13/35 | 19/39 | 34/41 | 70/139 | 70/139 |
| Unadjusted                                | 1.0   | 2.23 (0.65, 7.66) | 0.204 | 2.92 (0.89, 9.62) | 0.078 | 4.98 (1.57, 15.74) | 0.006 | 1.61 (1.19, 2.17) | 0.002 | 2.91 (1.59, 5.35) | 0.001 |
| Adjusted<sup>a</sup>                      | 1.0   | 1.45 (0.14, 15.09) | 0.754 | 6.82 (0.75, 62.30) | 0.089 | 15.49 (1.53, 156.16) | 0.020 | 2.77 (1.41, 5.42) | 0.030 | 7.90 (2.37, 26.38) | 0.001 |
| # Cases/Controls in subjects with CD4>350 | 10/86 | 15/75 | 17/64 | 17/18 | 59/243 | 59/243 |
| Unadjusted                                | 1.0   | 1.72 (0.73, 4.05) | 0.215 | 2.28 (0.98, 5.32) | 0.055 | 8.12 (3.19, 20.62) | <0.0001 | 1.88 (1.40, 2.53) | <0.0001 | 7.16 (2.34, 15.83) | <0.0001 |
| Adjusted<sup>a</sup>                      | 1.0   | 1.48 (0.14, 15.55) | 0.742 | 8.40 (0.92, 76.06) | 0.058 | 15.03 (1.49, 150.75) | 0.021 | 2.67 (1.38, 5.16) | 0.003 | 6.57 (2.04, 21.14) | 0.002 |

| Conditional logistic regression (Matched analysis)<sup>b</sup> | 4<sup>th</sup> Quartile | 3<sup>rd</sup> Quartile | 2<sup>nd</sup> Quartile | 1<sup>st</sup> Quartile | OR per Quartile Decrease | CD4/CD8 ratio <0.4 |
|---------------------------------------------------------------|------------------|------------------|------------------|------------------|---------------------|-----------------------|
| # Cases/Controls                                              | 17/33 | 25/25 | 24/26 | 34/16 | 100/100 | 100/100 |
| Primary                                                       | 1.0   | 2.45 (1.02, 5.86) | 0.044 | 2.28 (0.92, 5.67) | 0.076 | 11.46 (3.20, 40.97) | <0.0001 | 1.95 (1.23, 2.73) | <0.0001 | 3.43 (1.48, 7.96) | 0.004 |
| Adjusted<sup>a</sup>                                         | 1.0   | 3.04 (0.45, 20.43) | 0.252 | 3.56 (0.83, 32.57) | 0.084 | 31.99 (2.70, 378.85) | 0.006 | 2.89 (1.32, 6.17) | 0.007 | 5.43 (1.89, 26.99) | 0.004 |

Seven subjects from the 407 individuals were not included in the multivariate analysis due to missing data on CD4 nadir/cumulative ART exposure.

*Multivariate analysis adjusted by age, gender, nadir CD4+ cell count, date of ART initiation and cumulative ART exposure.

*Case-control substudy matched by age, gender, nadir CD4+ cell count and proximal CD4+ cell count.

*Conditional logistic regression analysis adjusted for date of ART initiation and cumulative ART exposure.

doi:10.1371/journal.pone.0085798.t003
CD4+ >350 cells/µL that a low CD4/CD8 ratio identified individuals with markers of age-associated disease (higher carotid intima-media thickness, higher arterial stiffness, and lower estimated glomerular filtration rate) [23].

These observations are physiopathologically supported by the fact that non-AIDS-related illnesses are mainly a consequence of the increased burden of age-associated disease and likely to be driven, at least in part, by persistent immune activation [10].

Levels and recurrence of T-cell activation is a major driving factor of immune senescence, which in turn have been associated with the CD4/CD8 ratio both in the general population [20] and in HIV-infected individuals [21,22]. While in healthy subjects these immune responses as a result of immune activation are followed by replenishment of the CD8+ T-cell pool from naive CD8+ T-cells [13], HIV-infected subjects show an impaired capacity to replace senescent T-cells, most probably due to reduced thymic output, which causes decreased levels of naive CD8+ T-cell and a compensatory expansion of memory CD8+ T-cells [13,36,37]. Since among immunological ART responders a low CD4/CD8 ratio is driven by very high numbers of CD8+ T-cells, this physiopathological cascade may explain why in this situation the risk of non-AIDS associated morbidity and mortality might be markedly increased, as they probably represent a population with expanded activated/senescent CD8+ T-cells. In our view, this particular population of immunological responders with low CD4/CD8 ratio – hence, very high CD8+ T-cells– could represent a clinical phenotype of immunological responders at higher risk for non-AIDS-associated morbidity and mortality.

Strengths of this study include the use of a prospective cohort subject to external audit of data and the ascertainment of serious non-fatal and fatal non-AIDS events, as well as the inclusion of a matched case/control subanalysis. There are also some limitations. Since we restricted the definition of non-AIDS events to ischemic heart disease, stroke, end-stage kidney disease, and non-AIDS malignancies, we cannot provide information on the value of the CD4/CD8 ratio to identify subjects at higher risk of other non-AIDS conditions. Also, we did not adjust the analyses by other potential risk factors for non-AIDS-related diseases. However, to date, no factor in the general population apart of age, gender and CMV serostatus have proved to impact on the CD4/CD8 ratio and our main objective was to analyze could provide additional information to nadir CD4 and CD4+ T-cell counts to identify subjects at increased risk of serious non-AIDS events. Also, cases showed significantly longer cumulative ART exposure than controls, in both the general sample and the nested matched study. Although we controlled the analyses for this variable, it is important to note that this difference between groups might have led to underestimate the association of a low CD4/CD8 ratio with non-AIDS-associated morbidity and mortality, given that in a recent study the CD4/CD8 ratio appeared to increase still after more than ten year of ART-mediated HIV RNA suppression [30], and in our study subjects who developed serious non-AIDS-related illnesses showed a lower CD4/CD8 ratio despite longer cumulative ART exposure. Lastly, data were retrieved from a single cohort of HIV-infected individuals, so before using the CD4/CD8 ratio as a surrogate of serious non-AIDS-related illnesses, these results should be reproduced in larger and prospective studies.

These findings have potential clinical implications, since patients with failure to increase the CD4/CD8 ratio despite achieving full immunovirological response to ART might benefit from screening programs and aggressive management of comorbid risk factors for age-associated disease. Moreover, considering previous data on the CD4/CD8 ratio in the general population [17,19,20] and our previous studies in HIV-infected individuals [21,22] subjects with low CD4/CD8 ratio despite otherwise successful ART might be of outstanding interest to be included in clinical trials aiming to reduce chronic immune activation. Of importance, since the CD4/CD8 ratio is available in routine clinical practice, its use as a predictor of non-AIDS associated morbidity and mortality might be easily implemented in clinical settings.

In conclusion, our results suggest that a low CD4/CD8 ratio might identify a subset of individuals at increased risk of non-AIDS-associated morbidity and mortality. The association between this ratio and the risk of serious non-AIDS events is robust and maintained within subjects with low CD4 nadir or those with higher CD4+ T-cell count.

Acknowledgments

This study would not have been possible without the collaboration of all the patients, medical and nursery staff and data managers who have taken part in the project.

Author Contributions

Conceived and designed the experiments: SSV SM. Analyzed the data: SSV AR TS. Wrote the paper: SSV. Contributed patient samples and data: SSV MPE FD JC AM AR JPM EN JH CQ SM. Generated the tables and figures, interpreted the data, and wrote the first draft of the manuscript: SSV. Reviewed, revised, and approved the final manuscript: SSV MPE FD JC AM AR JPM TS EN JMH CQ SM.

References

1. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, et al. (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53: 1120–1126. Available: http://www.ncbi.nlm.nih.gov/pubmed/21900276. Accessed 20 April 2013.
2. Hsue P, Hunt P, Schnell A, Kalapus SC, Hoh R, et al. (2009) Role of Viral Replication, Antiretroviral Therapy, and Immunodeficiency in HIV-Associated Atherosclerosis Prisciola. AIDS 23: 1059–1067. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891772/. Accessed 5 August 2010.
3. Seaberg EC, Muñoz A, Lu M, Detels R, Margończak JB, et al. (2005) Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19: 953–960. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1596577/. Accessed 27 October 2013.
4. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165: 1179–1184. Available: http://www.ncbi.nlm.nih.gov/pubmed/15911733. Accessed 27 October 2013.
5. Odden MC, Scherrer R, Baschetti P, Szczepczyk LA, Sidney S, et al. (2007) Cytostatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 167: 2213–2219. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3189482&tool=pmcentrez&rendertype=abstract. Accessed 27 October 2013.
6. Derks SG, Tracy R, Dowek DC (2013) Systemic Effects of Inflammation on Health during Chronic HIV Infection. Immunity 39: 633–645. Available: http://linkinghub.elsevier.com/retrieve/pii/S1074761313004354. Accessed 18 October 2013.
7. Hogg R, Lima V, Sterne J, Grabar S (2008) Life expectancy of individuals on antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293–299. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211967/?tool=pubmed. Accessed 27 August 2013.
8. Loehr N, Hansen AB, Pedersen G, Krumboe G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87–95.
9. Stephan C, Hill A, Xi N, van Delft Y, Moecklinghoff C (2012) Research letter: is long-term HIV RNA suppression? J Acquir Immune Defic Syndr 61: e73–5. Available: http://www.ncbi.nlm.nih.gov/pubmed/23183153. Accessed 27 October 2013.
Dock JN, Effros RB (2011) Role of CD8 T Cell Replicative Senescence in...

Phillips AN, Neaton J, Lundgren JD (2008) The role of HIV in serious diseases other than AIDS. AIDS 22: 2409–2418. Available: http://www.ncbi.nlm.nih.gov/pubmed/19336753. Accessed 13 May 2013.

Poses T, Robinson D, Stebbing J, Shamash J, Nelson M, et al. (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27: 884–890. Available: http://www.ncbi.nlm.nih.gov/pubmed/19114603. Accessed 27 October 2013.

Sarnak MJ, Levey AS, Schoenwirth AC, Corej J, Cubieon B, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169. Available: http://www.ncbi.nlm.nih.gov/pubmed/14581387. Accessed 18 October 2013.

Levy AS, Eckardt K-U, Tsukamoto Y, Levin A, Corh J, et al. (2005) Deﬁnition and classiﬁcation of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089–2100. Available: http://www.ncbi.nlm.nih.gov/pubmed/15822252. Accessed 24 October 2013.

Pavel P, Hansson DL, Sullivan PS, Novak RM, Moorman AC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148: 728–736. Available: http://www.ncbi.nlm.nih.gov/pubmed/18490686. Accessed 27 October 2013.

Baker J V, Peng G, Rapkin J, Abrams DI, Silverberg MJ, et al. (2008) CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22: 841–848. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3618460&tool=pmcentrez&rendertype=abstract. Accessed 27 October 2013.

Grund B, Peng G, Gibert CL, Hoy JF, Hasken RL, et al. (2009) Continuous antiretroviral therapy decreases bone mineral density. AIDS 23: 1519–1529. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2748536&tool=pmcentrez&rendertype=abstract. Accessed 27 October 2013.

Hsu P, Lo JC, Franklin A, Bolger AF, Martin JN, et al. (2004) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608. Available: http://www.ncbi.nlm.nih.gov/pubmed/15023877. Accessed 29 May 2013.

Taylor JM, Fahey JL, Detels R, Giorgio J V (1989) CD4 percentage, CD4 count, and CD4/CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 2: 114–124. Available: http://www.ncbi.nlm.nih.gov/pubmed/2495346. Accessed 27 October 2013.

Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrer A, et al. (2011) T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 203: 452–463. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3080892&tool=pmcentrez&rendertype=abstract. Accessed 11 May 2013.

Ferguson FG, Wldy A, Masson P, Olson J, Johansson B (1995) Immune parameters in a longitudinal study of a very old population of Swedish people: a longitudinal study. Exp Gerontol 29: 531–541. Available: http://www.ncbi.nlm.nih.gov/pubmed/7828662. Accessed 27 October 2013.

Wldy A, Johansson B, Pawelec G, et al. (2006) Longitudinal Studies of Clonally Expanded CD8 T Cells: Reveals a Reptoria Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly. J Immunol 176: 2643–2653. Available: http://www.jimmunol.org/content/176/4/2645.short. Accessed 28 August 2013.

Hsu P, Lo JC, Franklin A, Bolger AF, Martin JN, et al. (2008) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608. Available: http://www.ncbi.nlm.nih.gov/pubmed/15023877. Accessed 29 May 2013.

Taylor JM, Fahey JL, Detels R, Giorgio J V (1989) CD4 percentage, CD4 count, and CD4/CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 2: 114–124. Available: http://www.ncbi.nlm.nih.gov/pubmed/2495346. Accessed 27 October 2013.

Hsu P, Lo JC, Franklin A, Bolger AF, Martin JN, et al. (2004) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608. Available: http://www.ncbi.nlm.nih.gov/pubmed/15023877. Accessed 29 May 2013.

Taylor JM, Fahey JL, Detels R, Giorgio J V (1989) CD4 percentage, CD4 count, and CD4/CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 2: 114–124. Available: http://www.ncbi.nlm.nih.gov/pubmed/2495346. Accessed 27 October 2013.

Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett R, et al. (2011) T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 203: 452–463. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3080892&tool=pmcentrez&rendertype=abstract. Accessed 11 May 2013.

Ferguson FG, Wldy A, Masson P, Olson J, Johansson B (1995) Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci 60: 536–543.

Fernandez-Villar S, Gutierrez C, Valcuch A, Hernández-Novoa B, Diaz L, et al. (2013) The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 66: 57–66. Available: http://www.ncbi.nlm.nih.gov/pubmed/23046986. Accessed 17 July 2013.

Sanz T, Serrano-Villar S, Diaz L, González-Tome MI, Gurbindo MD, et al. (2013) The CD4/CD8 Ratio as a Marker T-cell Activation, Senescence and Activation/Exhaustion in Treated HIV-Infected Children and Young Adults. AIDS 27: 1513–1516. Available: http://www.ncbi.nlm.nih.gov/pubmed/23435292. Accessed 26 February 2013.

Serrano-Villar S, Moreno S, Fuentes-Ferrer M, Sánchez-Marcos C, Avila M, et al. (2014) The CD4/CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med 15: 40–49. Available: http://www.ncbi.nlm.nih.gov/pubmed/24007533. Accessed 10 December 2013.

Lo J, Abbara S, Shtrumman L, Soni A, Wei J, et al. (2010) Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 24: 243–253. Available: http://www.ncbi.nlm.nih.gov/pubmed/19996049. Accessed 30 May 2011.

Clifford GM, Rickenbach M, Lise M, Dal Maso L, Bategga M, et al. (2009) Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 113: 5377–5374. Available: http://www.ncbi.nlm.nih.gov/pubmed/19336753. Accessed 13 May 2013.

Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 113: 5377–5374. Available: http://www.ncbi.nlm.nih.gov/pubmed/19336753. Accessed 13 May 2013.

Levy AS, Eckardt K-U, Tsukamoto Y, Levin A, Corh J, et al. (2005) Deﬁnition and classiﬁcation of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089–2100. Available: http://www.ncbi.nlm.nih.gov/pubmed/15822252. Accessed 24 October 2013.

Pavel P, Hansson DL, Sullivan PS, Novak RM, Moorman AC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148: 728–736. Available: http://www.ncbi.nlm.nih.gov/pubmed/18490686. Accessed 27 October 2013.